Advertisement

Topics

BATs in Patients With Breast Cancer and Leptomeningeal Metastases

2018-09-12 01:58:12 | BioPortfolio

Published on BioPortfolio: 2018-09-12T01:58:12-0400

Clinical Trials [5013 Associated Clinical Trials listed on BioPortfolio]

Her2-BATS and Pembrolizumab in Metastatic Breast Cancer

This proposal uses HER2Bi armed activated T-cells (HER2 BATs) to target breast cancer in combination with pembrolizumab (PBZ) in women with metastatic breast cancer (MBC). Phase I will det...

A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer

The primary purpose of this study is to identify the maximum tolerated dose (MTD) of both intravenous and oral panobinostat when given in combination with trastuzumab and paclitaxel. The ...

A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer

This is a randomized, open-label, parallel, multi-center study, aims to evaluate the efficacy and safety of metronomic chemotherapy with oral Navelbine versus intermittent oral Navelbine i...

Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer

This is an open-label, single arm, phase 2 trial that will include pre or post-menopausal female subjects, that have ER-positive, HER2-negative early breast cancer. Subject will receive 4 ...

PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer

HER2 gene amplification increases VEGF production in breast cancers; combined inhibition of HER2 and VEGF enhances response in xenograft models. The upregulation of VEGF in HER2-overexpres...

PubMed Articles [17686 Associated PubMed Articles listed on BioPortfolio]

Monitoring Src status after dasatinib treatment in HER2+ breast cancer with Zr-trastuzumab PET imaging.

De novo or acquired resistance in breast cancer leads to treatment failures and disease progression. In human epidermal growth factor receptor 2 (HER2)-positive (HER2+) breast cancer, Src, a non-recep...

The FDA-Approved Breast Cancer HER2 Evaluation Kit (HercepTest; Dako) May Miss Some HER2-Positive Breast Cancers.

Accurate evaluation of human epidermal growth factor receptor 2 (HER2) in breast cancer is critical.

Role of MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer.

Resistance to HER2-targeted therapy with trastuzumab still remains a major challenge in HER2-amplified tumors. Here we investigated the potential role of MEL-18, a polycomb group gene, as a novel prog...

Patients who achieved long-term clinical complete response and subsequently terminated multidisciplinary and anti-HER2 therapy for metastatic breast cancer: A case series.

Human epidermal growth factor receptor 2 (HER2) -positive breast cancers tend to be more aggressive and more likely to recur than HER2-negative breast cancers. However, novel anti-HER2 therapies have ...

HER2 positive breast cancer patients having HER2 loss after neoadjuvant chemotherapy should still be treated with adjuvant anti-HER2 treatment.

Medical and Biotech [MESH] Definitions

A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.

Abnormal accumulation of lymph in the arm, shoulder and breast area associated with surgical or radiation breast cancer treatments (e.g., MASTECTOMY).

Metastatic breast cancer characterized by EDEMA and ERYTHEMA of the affected breast due to LYMPHATIC METASTASIS and eventual obstruction of LYMPHATIC VESSELS by the cancer cells.

Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).

Use of ultrasound for imaging the breast. The most frequent application is the diagnosis of neoplasms of the female breast.

More From BioPortfolio on "BATs in Patients With Breast Cancer and Leptomeningeal Metastases"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial